论文部分内容阅读
目的观察褪黑素（ＭＬＴ）对不能手术的晚期肝细胞癌（ＨＣＣ）患者的治疗效果。方法６０例ＨＣＣ患者，ＭＬＴ组３１例，以ＭＬＴ２０ｍｇ每晚口服一次，辅以对症支持治疗，直至病情恶化；对照组２９例，单纯对症支持治疗。结果ＭＬＴ组与对照组的部分缓解率（ＰＲ）分别为２５．８％、３．４％（Ｐ＜０．０１），中位生存期分别为１０．７月和３．８月（Ｐ＜０．０１），半年和一年生存率分别依次为５９．６％与１７．４％（Ｐ＜０．０５），３２．４％与０％（Ｐ＜０．００１）。１２例有腹水者经ＭＬＴ治疗后腹水完全消失，所有患者生活质量明显改善，未见明显毒副反应。结论ＭＬＴ为不能手术的晚期ＨＣＣ患者的治疗，提供一条新的且有效的方法和途径。
Objective To observe the therapeutic effect of melatonin (MLT) on patients with inoperable advanced hepatocellular carcinoma (HCC). Methods 60 patients with HCC and 31 patients with MLT were treated with oral MLT 20mg once per night, supplemented with symptomatic and supportive therapy until the condition deteriorated, and 29 patients in the control group were treated with symptomatic support alone. Results The partial remission rate (PR) of MLT and control groups was 25.8% and 3.4% (P<0.01), and the median survival time was 10.7 months and 3.8 months, respectively (P< 0.01), six months and one year survival rates were 59.6% and 17.4% (P <0.05), 32.4% and 0%, respectively (P <0.001). Twelve patients with ascites had complete disappearance of ascites after MLT treatment. The quality of life of all patients was significantly improved and no obvious side effects were seen. Conclusion MLT provides a new and effective method and approach for the treatment of inoperable advanced HCC patients.